^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR A750P

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY). (ASCO 2023)
    Genotype-matched targeted therapies to overcome treatment-resistance have not been established, except osimertinib against EGFR T790M mutation... LC-SCRUM-TRY contributes to the clinical development of precision medicine to overcome drug resistance, especially for EGFR-mutated NSCLC resistant to EGFR-TKI. This screening platform also help to practice precision medicine for patients initially diagnosed as driver-negative. Clinical trial information: UMIN000041957.
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
    |
    BRAF V600E • EGFR mutation • KRAS G12C • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR T790M • MET exon 14 mutation • EGFR C797S • KRAS G12 • HER-2 exon 20 mutation • EGFR L718Q • EGFR A750P • HER-2 exon 23 mutation
    |
    Guardant360® CDx • Oncomine Precision Assay
    |
    Tagrisso (osimertinib)
    over2years
    A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies (clinicaltrials.gov)
    P2, N=1, Terminated, Spectrum Pharmaceuticals, Inc | N=150 --> 1 | Trial completion date: Dec 2023 --> Mar 2022 | Recruiting --> Terminated | Trial primary completion date: Jun 2023 --> Mar 2022; Strategic business decision (unrelated to safety)
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability)
    |
    HER-2 positive • EGFR mutation • MSI-H/dMMR • HER-2 negative • EGFR L858R • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • ER negative • EGFR S768I • HER-2 S310F • EGFR positive • HER-2 I655V • HER-2 L869R • HER-2 V842I • EGFR P596L • EGFR R222C • EGFR A750P • EGFR E746 • EGFR L833V • HER-2 R678Q • PGR negative • EGFR V774M
    |
    Pozenveo (poziotinib) • loperamide
    over3years
    [VIRTUAL] Mutational landscape of EGFR exons 01-28 in a genetically admixed NSCLC cohort unveils uncommon variants with impact on patient’s outcome (EACR 2021)
    The chi-square including the covariates was 14.85 (P<0.01). Conclusion Our data indicated that EGFR uncommon mutations were widely distributed in Brazilian patients with NSCLC and may contribute to new perspectives on precision treatment.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR S768I • EGFR exon 18 mutation • EGFR G719C • EGFR A750P
    over3years
    [VIRTUAL] Mutational landscape of EGFR exons 01-28 in a genetically admixed NSCLC cohort unveils uncommon variants with impact on patient’s outcome (EACR 2021)
    The chi-square including the covariates was 14.85 (P<0.01). Conclusion Our data indicated that EGFR uncommon mutations were widely distributed in Brazilian patients with NSCLC and may contribute to new perspectives on precision treatment.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR S768I • EGFR exon 18 mutation • EGFR G719C • EGFR A750P
    over3years
    [VIRTUAL] Mutational landscape of EGFR exons 01-28 in a genetically admixed NSCLC cohort unveils uncommon variants with impact on patient’s outcome (EACR 2021)
    The chi-square including the covariates was 14.85 (P<0.01). Conclusion Our data indicated that EGFR uncommon mutations were widely distributed in Brazilian patients with NSCLC and may contribute to new perspectives on precision treatment.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR S768I • EGFR exon 18 mutation • EGFR G719C • EGFR A750P
    over3years
    [VIRTUAL] Mutational landscape of EGFR exons 01-28 in a genetically admixed NSCLC cohort unveils uncommon variants with impact on patient’s outcome (EACR 2021)
    The chi-square including the covariates was 14.85 (P<0.01). Conclusion Our data indicated that EGFR uncommon mutations were widely distributed in Brazilian patients with NSCLC and may contribute to new perspectives on precision treatment.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR S768I • EGFR exon 18 mutation • EGFR G719C • EGFR A750P
    almost4years
    [VIRTUAL] Comprehensive Investigation of Uncommon EGFR Mutations in 14,429 Chinese Lung Cancer Patients (IASLC-WCLC 2020)
    Conclusion More and more uncommon EGFR mutations are identified owing to the development of NGS. This is the largest NGS-based cohort of Chinese lung cancers for investigating uncommon EGFR mutations, and 5.48% patients that with EGFR-TKI-sensitive uncommon mutations alone were found, which should be informative for the clinical therapies.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719S • EGFR exon 18 mutation • EGFR G719C • EGFR A750P • EGFR E746 • EGFR L747_P753delinsS